Skip to main content

Ionis Pharmaceuticals Value Stock - Dividend - Research Selection

Ionis Pharmaceuticals

ISIN: US4622221004, WKN: A2ACMZ

Market price date: 19.01.2021
Market price: 61,03 USD




Ionis Pharmaceuticals Fundamental data and company key figures of the share

Annual reports in USD
Key figures 05-03-2020
Cash flow
Net operating cash flow 345.720.000
Capital Expenditures -30.905.000
Free cash flow 314.815.008
Balance sheet
Total Equity 1.471.090.000
Liabilities & Shareholders equity 3.233.110.000
Income statement
Net income 294.146.000
Eps (diluted) 2,080
Diluted shares outstanding 141.416.000
Net sales/revenue 1.122.600.000

Fundamental ratios calculated on: 19-01-2021

Ratios
Key figures 19-01-2021
Cash flow
P/C 24,96
   
P/FC 27,42
Balance sheet
ROI9,10
ROE45,50
Income statement
P/E29,34
Div. Yield0,00%
P/B5,87
P/S7,69


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolIONS
Market Capitalization8.665.972.736,00 USD
CountryUnited States
IndicesNASDAQ Comp.
SectorsPharma
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internetwww.isispharm.com


Description of the company

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. It is also developing inotersen, an antisense drug Ionis to treat patients with hereditary transthyretin amyloidosis; and volanesorsen, an antisense drug for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. In addition, the company is developing drugs for various indications, such as cardiometabolic diseases caused by lipid disorders; cardiovascular disease, clotting disorders, and Alzheimer\'s and Parkinson\'s diseases; and acromegaly, amyotrophic lateral sclerosis, beta-thalassemia, and Huntington\'s disease. Ionis Pharmaceuticals, Inc. has a collaboration agreement with AstraZeneca to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, and cancer; and Biogen Inc. to develop and commercialize therapies for neurological disorders, SMA, and neurodegenerative diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.isispharm.com